SEC Tracker
Get the app

Ultragenyx Pharmaceutical RARE

Ultragenyx Pharmaceutical announces restructuring plan

Item 2.01 Completes acquisition or sale, Item 2.02 Reports results, Item 2.05 Exit or restructuring costs

Form
8-K
Filed
Importance
Major
  1. Workforce reduction of approximately 20% of employees
  2. Estimated $25 million in restructuring charges
  3. Restructuring charges expected in Q4 2026

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Ultragenyx Pharmaceutical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 3 claims matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, Ultragenyx reported revenue of $214.0 million and a net loss of $92.0 million.
  • The company's operating margin was -35.0% and net margin was -43.0% for the quarter.
  • Revenue increased 28.1% compared to the same period a year earlier.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
  2. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  3. Vaxcyte PCVX public float $3.7B, Jun 30, 2025
  4. Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
  5. Viking Therapeutics VKTX public float $3.0B, Jun 30, 2025